Online inquiry

IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6047MR)

This product GTTS-WQ6047MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Giant cell arteritis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6047MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15196MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ10038MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ4924MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ12303MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ10224MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ7584MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ1866MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ11299MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-522
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW